TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02859142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling Sessions
Description: One-to-one behavioral counseling sessions with a trained therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Counseling Sessions
Description: One-to-one behavioral counseling sessions with a trained therapist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicodermCQ
Description: Nicotine patches provided over 12 week participation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicodermCQ
Description: Nicotine patches provided over 12 week participation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Study: NCT06328465

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diffusion whole body MRI
Description: Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
Study: NCT03062384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AT-001

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01527409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored health partnership program
Description: When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Usual care and health education workshop
Description: While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group.
Study: NCT01412086

Intervention type: DRUG
Intervention: No Intervention
Description: No Intervention.
Study: NCT00228917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax-ACWY
Description: Meningococcal Serogroups A, C, W-135 and Y Vaccine
Study: NCT00463749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcystein
Description: high-dose N-Acetylcystein during PCI and for 2/day for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl as placebo
Study: NCT04244513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
Study: NCT00914862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.
Study: NCT03178747

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: working solution methylene blue

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Methylene blue
Description: working solution methylene blue

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Giemsa stain
Description: working solution Giemsa stain (Wolbach's modification)

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Giemsa stain
Description: working solution Giemsa stain (Wolbach's modification)
Study: NCT04263701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Conventional physiotherapy exercises for children with cerebral palsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
Study: NCT03830554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Atlas cedar wood essential oil (Cedrus Atantica)
Description: At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
Study: NCT01141881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator,bevacizumab ,follow up
Description: 25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
Study: NCT04242004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) capsules
Description: Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy oil capsules
Description: The placebo was identical looking capsules that contained soy oil
Study: NCT03198741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin + clopidogrel
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Description: After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study: NCT01324388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT00728130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck dissection of at least the ipsilateral sub-level 1B
Description: neck dissection of at least the ipsilateral sub-level 1B
Study: NCT01715311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol once daily via single-dose dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules for inhalation once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules for inhalation once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium capsules for inhalation once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol capsules for inhalation once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol capsules for inhalation once daily
Study: NCT03760120

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PEP-MASK

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP-MASK
Study: NCT02044133

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage Vitamine D

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage Vitamine D
Study: NCT03139149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed.
Study: NCT02237937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study: NCT05982002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave
Description: ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity aerobic exercise
Description: Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Description: Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
Study: NCT02402283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole benzoate oral granules
Description: Single oral dose of 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 400 mg Tablets
Description: Single oral dose of 400 mg
Study: NCT04407234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen administered orally.
Study: NCT01705912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete intervention
Description: The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic intervention
Description: The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
Study: NCT02262754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06372865 and placebo for naproxen daily
Study: NCT03139149

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-ray diagnostics
Description: X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-ray diagnostics
Description: X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
Study: NCT02262754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500 mg BID for 4 weeks
Study: NCT01858753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fibroblasts

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous fibroblasts

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo sterile saline
Study: NCT04189029

Intervention type: OTHER
Intervention: Extensive phenotyping
Description: Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.

Intervention type: OTHER
Intervention: Extensive phenotyping
Description: Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.

Intervention type: OTHER
Intervention: Extensive phenotyping
Description: Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
Study: NCT03931798

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Scanning Test
Description: The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
Study: NCT02237937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptylinoxide
Study: NCT03392623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: topical administration in melasma lesions

Intervention type: DEVICE
Group type: OTHER
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter
Study: NCT02237937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptylinoxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimipramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimipramine
Study: NCT01270906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHIR-258 (TKI258)
Study: NCT01329107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Description: Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care.
Study: NCT01366456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion
Description: Comparison of different kinds of moxibustion
Study: NCT03139149

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computer tomography
Description: Computer tomography of abdomen with iv contrast

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computer tomography
Description: Computer tomography of abdomen with iv contrast
Study: NCT03392623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter
Study: NCT01529866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Abutment Connection implant
Description: New abutment connection implant
Study: NCT03139149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the abdomen (2 times)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the abdomen (2 times)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General and biochemical blood test
Description: General blood test and biochemical blood test 2 times a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General and biochemical blood test
Description: General blood test and biochemical blood test 2 times a day
Study: NCT01529866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain Tapered implant
Description: Nanotite certain tapered (standard abutment connection) implant
Study: NCT04434365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statins once daily for 12±1 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statins once daily for 12±1 weeks.
Study: NCT01456104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Description: Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
Study: NCT04136925

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire before and after race
Study: NCT01994629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: MenACWY-CRM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: MenACWY-TT
Study: NCT03169465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open approach
Description: open excision of the bursa and deformity then debridement of Achilles tendon